Gynecologic Oncology

Article	Citations
Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer	155
Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency	116
Association between time to adjuvant chemotherapy and outcomes in low grade ovarian cancer	83
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy	71
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results	70
Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial	69
Innovations in surgery and peri-operative care: A technical gimmick or true oncology advance?	68
Platinum resistance: The great prognostic equalizer? Association between early disease characteristics and survival after diagnosis of platinum resistance in ovarian cancer	67
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	66
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	64
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis	60
Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis	59
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group	58
CRABP2 – A novel biomarker for high-risk endometrial cancer	56
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer	54
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity	54
Impact of the 2023 FIGO staging on a high-risk endometrial cancer cohort	52
Clinical characteristics of ovarian cancer patients with pathologic complete response after neoadjuvant chemotherapy	51
Evaluating nutrition in advanced ovarian cancer: Which biomarker works best?	49
Barriers faced by obstetrics and gynecology providers and trainees in providing HPV vaccination to patients aged 27–45 years	48
Variables impacting postoperative length of stay for gynecologic cancer patients in the era of same day minimally invasive hysterectomy	48
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	45
The outcome of waiting for radiotherapy in locally advanced cervical cancer	42
Economic burden of cervical cancer in Latin America: A real-world study	42
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	42

Chemoradiotherapy response and the tumor microenvironment in a novel immunocompetent mouse model of cervical cancer	41
Fertility-sparing surgery versus standard surgery for early-stage cervical cancer: Five-year life expectancies by tumor size	41
Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with	41
Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial	39
Successful implementation of a goals-to-discharge patient checklist following surgery for gynecologic cancer	38
Assessment of endocrine toxicities among gynecologic oncology patients receiving immunotherapy	38
RE1 transcription factor is decreased in endometrial cancer	38
Factors associated with human papillomavirus vaccination: Determining the effect of implicit and explicit racial bias and state laws around vaccination	37
Finding a needle in the haystack: Identifying risk of MDS/AML after PARP inhibitor treatment	36
A phase II, two-stage study of avelumab and axitinib among patients with mismatch repair proficient recurrent or persistent endometrial cancer: Final efficacy analysis and correlative studies	36
A randomized controlled trial of wound infiltration with liposomal bupivacaine with or without intrathecal analgesia in patients undergoing laparotomy for advanced gynecologic malignancy	36
Population-based BRCA1 and BRCA2 genetic testing is cost-effective in Canada	34
Endometrial pathology among premenopausal patients seeking emergency care for abnormal uterine bleeding: High risk of endometrial malignancy and premalignancy	34
Focal adhesion kinase inhibitors as maintenance therapy in a homologous recombination repair proficient high-grade serous ovarian cancer murine model	34
The prognostic value of circulating minimal residual disease in first-line treatment of ovarian cancer	34
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	33
Impact of geographic region of birth on overall survival among Hispanic women with endometrial cancer	32
The effect of Medicaid expansion on the receipt of guideline-concordant care among patients with cervical cancer in the United States: A difference-in-difference analysis of the National Cancer Databa	32
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer	32
BRCA and homologous recombination repair deficiency testing in advanced ovarian cancer: A real-world data analysis	32
Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma	32
Language as a barrier to clinical trial enrollment: Identifying methods to improve clinical trial enrollment in minority and non-English-speaking patients	31
PDE1A in epithelial ovarian cancer: Oncogenic role, metastatic association, and potential as a prognostic biomarker and therapeutic target	30
A phase II study evaluating carboplatin/paclitaxel/pembrolizumab among newly diagnosed stage III/IV epithelial ovarian cancer patients receiving neoadjuvant chemotherapy followed by olaparib/pembroliz	30
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	30
Weakly supervised deep learning-based prognostic model for AI-assisted prospective clinical investigation of cervical cancer	29
Understanding real-world treatment patterns of patients with advanced ovarian cancer in the first-line maintenance setting: The FIRST STEP Study	29
Group Appointments for Cancer Survivorship Equity (GRACE): Evaluating the use of group medical visits in rural and underserved gynecologic cancer survivors	29
Changes in HRD status during treatment for ovarian high-grade serous carcinoma	29
MHC class II expression as a predictor of response to immune checkpoint inhibition in gynecologic malignancies	29
The cervical and tumor-associated microbiome among Botswanan women with HIV diagnosed with high-grade cervical dysplasia and squamous cell carcinoma of the cervix	29
HIF2A shows potential tumor-promoting effect and could be a poor prognostic factor in ovarian clear cell carcinoma	28
A phase Ib/II single-arm study of cabozantinib plus dostarlimab among women with recurrent gynecologic carcinosarcoma	28
Chromobox2 (CBX2)/Y-box binding protein 1 (YBX1) axis drives chemoresistance in high-grade serous carcinoma: Exploring novel therapeutic strategies	28
Therapeutic vaccination for the elimination of HPV16+ high-grade dysplasia: A phase I clinical trial of the DNA vaccine pNGVL4aCRTE6E7L2, administered via the TriGrid™ electroporation device	28
Knockout of cancer biomarker HE4 in the gynecologic tract leads to fibrosis and early infertility	28
Supervised machine learning with a novel set of 20 genes predicts the likelihood of early or late recurrence of high-grade serous ovarian cancer	28
Deep quantitative proteomics identifies elevated MUC16 in low- compared to high-grade serous ovarian carcinoma	28
Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high-grade serous ovarian carcinoma	28
Targeting Mediator kinases CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma	28
Survival analysis of a prospective intraoperative algorithm to guide surgical staging in early-stage endometrial cancer	28
Phase I study of the tissue factor-targeting antibody-drug conjugate XB002 among patients with advanced solid tumors (JEWEL-101): Design of expansion cohorts for endometrial, epithelial ovarian, and c	27
What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?	27
A new standard for surgical site infection prevention in gynecologic cancer: Metronidazole plus cefazolin better than cefazolin alone	27
Hypoalbuminemia alone is not a contraindication to primary cytoreductive surgery in advanced ovarian cancer	27
The role of NKG2D-MICA in the immune escape mechanism of epithelial ovarian cancer	27
Pamiparib in combination with surufatinib among patients with platinum-resistant ovarian cancer who received prior PARP inhibitors: A multicenter, single-arm, phase Ib/II trial (POST-PARPi Trial)	27
Cost-effectiveness analysis of cancer susceptibility gene-specific prevention strategies for ovarian and breast cancer	26
Evaluation of physical function and quality of life before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2–	26
BRCA awareness and testing experience in the UK Jewish population: A qualitative study	26

A predictive nomogram for endometrial cancer based on preoperative assessment among patients with endometrial intraepithelial neoplasia	26
Perioperative outcomes in gynecologic pelvic exenteration before and after Enhanced Recovery After Surgery implementation	25
Can CA-125/CEA ratio be used for the differential diagnosis between ovarian and non-ovarian cancers? A cross-sectional study	25
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III tria	25
Characteristics and outcomes of geriatric patients with advanced solid tumors enrolled in a single-center, phase I clinical trial program	25
Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology cli	25
A more accurate measure of endometrial cancer incidence rates in New Mexico: A hysterectomy-corrected analysis	25
Analysis of Prevalence of Variants of Uncertain Significance in an ethnically and socio-demographically diverse Hereditary Breast and Ovarian Cancer Program	25
Uterine cancer among Asian Americans: Disparities & clinical characteristics and disease presentations	25
Feasibility of obesity management with endocrinology referral for prescription of weight loss medications in an ethnically and racially diverse gynecologic oncology clinic	25
Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study	24
Diagnostic and prognostic accuracy of exosomal miRNA-based signature for endometrial cancer	24
Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study	24
Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal	24
Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database	24
What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy	24
Duration of bleeding prior to endometrial cancer diagnosis: An opportunity to rethink our approach to detection and diagnosis in at-risk groups	24
Protein expression by immunohistochemistry is associated with and  gene amplification	24
Genetic variants associated with recurrence of grade 1–2, stage 1A endometrioid adenocarcinoma of the uterus	23
Editorial Board	23
Disparities in palliative care utilization and outcomes during inpatient hospitalization for gynecologic malignancies in the United States, 2009–2018	23
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)	23
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)	23
Lymph node dissection in uterine leiomyosarcomas: A matched-pair study	23
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)	23
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	23
What do you know? The role of race/ethnicity in clinical trial knowledge among patients with a gynecologic malignancy	23
Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer	23
The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens	23
Role of immunotherapy for lymph-node positive vulvar melanoma: Utilization and outcomes (154)	23
We Can’t Just Wait This Out: Burnout and Fulfillment among SGO Members over the First Two Waves of the COVID-19 Pandemic (051)	22
Anlotinib in patients with recurrent platinum-resistant or platinum-refractory ovarian carcinoma: A prospective, single-center, single-arm, phase II clinical trial (033)	22
Socio-ecological model of barriers to cascade testing for hereditary cancer syndromes: Systematic review of the literature (057)	22
Patient Reported Outcomes and Final Results of Phase 1 Evaluation of the Safety and Clinical Activity of Sapanisertib in Combination with Serabelisib and Paclitaxel in Patients with Advanced Ovarian,	22
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials	22
Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer	22
Pilot Cervical Cancer Navigation Program Outcomes from a Tertiary Tanzanian Academic Institute (037)	22
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Outcomes Across Three Academic Institutes Among Frail and Non-Frail Patients (064)	21
RNAseq correlative biomarkers IFIT1B and VSTM5 predict progression free survival and clinical benefit in a multi-site Phase I/II trial of Olaparib and Tremelimumab for gBRCAm recurrent ovarian cancer	21
Universal thromboprophylaxis in ovarian cancer patients before and after surgery?	21
Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1 (077)	21
Efficacy and safety of serplulimab (an anti-PD-1 antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after f	21
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial	21
Geospatial approaches for surveillance of disparities in clinical trial enrollment (058)	21
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	21
In the patient’s shoes: The impact of hospital proximity and volume on stage I endometrial cancer care patterns and outcomes	21
O5 Does race impact surgical management of cervical cancer: An SGO clinical outcomes registry analysis	20
O4 Impact of adjuvant chemotherapy in treatment of serous tubal intraepithelial carcinoma	20
P15 Use of romiplostim in chemotherapy-induced thrombocytopenia in gynecologic and breast cancers	20
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	20
P9 Access to gynecologic oncologist specialists for patients with a new endometrial cancer diagnosis in the United States	19
P30 House of cards? Final histology may differ from initial biopsy in ovarian cancer patients undergoing neoadjuvant chemotherapy	19
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial	19
Stage IV gynecologic cancers patients who subsequently died from disease: lessons learned from their health care journey	19
O1 Identifying barriers individuals face in accessing fertility care after a gynecologic cancer diagnosis	19
P18 Feasibility and acceptability of referral to endocrinology for prescription of weight loss medications in an ethnically and racially diverse gynecologic oncology clinic	19
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study	19
Redefining readmissions in gynecologic cancer: readmissions resulting in hospital-to-hospice transitions may represent high value care	19
TOC	19
P2 Clinical utility of universal genetic predisposition testing in cancer patients and impact on patients with gynecologic malignancies	19
P27 Patterns of care and predictors of overall survival in women diagnosed with serous tubal intra-epithelial carcinoma (STIC)	19
Sentinel lymph node procedures in endometrial cancer: an international multicenter experience	19
Safety of fertility sparing management in invasive mucinous ovarian carcinoma	19
Survival differences by race and surgical approach in early-stage operable cervical Cancer	18
The role of obesity in treatment planning for early-stage cervical cancer	18
Sentinel lymph node biopsy versus complete lymphadenectomy in high grade endometrial cancer: a systematic review and meta-analysis of performance characteristics	18
The impact of a universal inpatient palliative care consultation protocol for patients with gynecologic cancer: a quality improvement project	18
The impact of race on high-risk types of uterine cancer is modified in non-Hispanic Black and non-Hispanic White women with multiple malignancies	18
Sentinel lymph node mapping detection and recurrence rates in clinical stage I endometrial cancer	18
Standard of care in locally advanced cervical cancer and unmet needs: a systematic literature review of phase III randomized controlled trials	18
The increasing rate of metastatic vulvar cancer in the United States: what factors are responsible?	18
Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus	18
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study	18
An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China (1112)	17
The impact of delayed surgical treatment of suspected stage I ovarian cancer: lessons for a pandemic	17
Tumor characteristics and survival in patients with extranodal non-Hodgkin lymphoma of the female reproductive tract	17
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement	17
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	17
Integration of genomic and clinical data to predict endometrial cancer outcomes (1121)	17
The value of preoperative imaging for identification of metastatic disease and prediction of adjuvant therapy in clinical early-stage cervical cancer	17

Aberrant nuclear β-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers – A retrospective single-institutional study	17
Evaluating the impact of epigenetics: Does MLH1 promoter hypermethylation negate stage in early endometrial cancer? (1107)	17
Cervical cancer in young women: Are there differences in demographic, histologic factors and clinical characteristics? (1114)	17
Effect of transversus abdominis plane block on postoperative outcomes in gynecologic oncology patients managed on an Enhanced Recovery After Surgery pathway	17
The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter	17
The levonorgestrel intrauterine system (LNG-IUS) for prevention of endometrial cancer in women with obesity is cost effective	17
Outcomes of adjuvant chemotherapy only after radical surgery for stage IIIC cervical cancer patients (1101)	17
The role of neoadjuvant chemotherapy in patients with high-grade neuroendocrine carcinoma of the uterine cervix (1313)	16
Impact of neoadjuvant chemotherapy duration on the survival of patients with advanced stage high-grade serous or endometrioid ovarian carcinoma (359)	16
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary pe	16
Biomarker testing to guide first-line PARP inhibitor maintenance for patients with advanced ovarian cancer after response to first- line platinum chemotherapy: A cost-effectiveness study (382)	16
Does mismatch repair deficiency have similar prognostic value for Black endometrial cancer patients compared to non-Black counterparts from the deep South? (2118)	16
Patterns of spread and genetic mutations of primary endometrioid carcinomas of the ovary (168)	16
Anlotinib plus chemoradiotherapy in the treatment for FIGO stage IB3 and IIB-IVA cervical cancer: A prospective single-arm, single-center, exploratory phase II trial (299)	16
The role of adjuvant chemotherapy in endometrial cancer following pre-operative neoadjuvant chemoradiation therapy (1137)	16
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup	16
Comprehensive genomic profiling (CGP) via peripheral blood liquid biopsies identifies therapeutically relevant genomic alterations in tubo-ovarian and peritoneal cancer	16
A Phase I/II, multicenter, open-label study of REGN5668 (R5668; mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab or REGN4018 (R4018; MUC16 x CD3 bsAb) in patients with recurrent ovaria	16
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)	16
Landscape of Genomic Alterations and Biomarkers in Endometrial Cancer (EC) Identified by Comprehensive Genomic Profiling (CGP) of Peripheral Blood Biopsies (181)	16
Discovery of small molecule therapies targeting the Kinase pathway in ovarian cancer (310)	16
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)	16
Separating the BRCA1 and BRCA2 phenotype: a genomic pathway analysis	16
Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary safety results from the phase II LIGHT study	16
The rising incidence and risk of high-risk uterine cancer: A case for targeted screening (1322)	16
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting	15
Editorial board	15
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	15
Increasing volume and the role of gynecologic oncologists in peripartum hysterectomies – A single center study of 109 cases over 7 years (008)	15
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population	15
Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts	15
Use of an individualized algorithm for postoperative prescriptions in gynecologic oncology patients: prescribing practices, clinical encounters, and patient satisfaction	15
Preventing the primary debulking: An educational initiative to increase rates of salpingectomy at cesarean delivery	15
Concurrent uterine surgery and uptake of hormone therapy in patients undergoing bilateral salpingo-oophorectomy for risk-reducing or therapeutic indications	15
Use of an opioid disposal bag for leftover pills in gynecologic oncology patients undergoing surgery	15
P28 Investigating molecular profiles of subtypes of mucosal melanomas: is vulvovaginal melanoma a distinct entity?	15
O1 Alarming trends in high-risk uterine cancer histology in Black women in the US: is obesity responsible?	15
Utility of intraoperative frozen section of the inguinofemoral sentinel lymph node in vulvar cancer: a retrospective cohort	15
Validation of the prognostic value of the 2018 FIGO stage IIIC in patients with cervical cancer	15
Primary vaginal sarcoma in a single center (143)	15
Provider compliance with a tailored opioid prescribing calculator in gynecologic surgery	15
P16 Optimizing prehabilitation in gynecologic oncology	15
P9 Mixed endometrial cancer a rare histology with the largest racial disparity in survival	15
Verification of HPV16 as a good prognostic factor for cervical adeno-adenosquamous carcinoma via an international collaborative study	15
Using restrictive opioid protocols for postsurgical pain management does not compromise patient reported outcomes	15
RF3 The association of tumor mutational burden, microsatellite stability, and mismatch repair deficiency in an endometrial cancer patient cohort	15
Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic	15
Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer	14
Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer	14
Limiting pregnancy termination rights in patients with cancer: The disproportionate impact on Hispanic women with cervical cancer (167)	14
Multimodality adjuvant treatment is associated with a survival benefit for patients with stage IIIC uterine carcinosarcoma	14
Opioid analgesics following surgery for gynecologic cancer patients at a university health center: have we altered our prescribing patterns in this patient population?	14
Prognostic factors associated with overall survival in presumed early stage, high-grade serous ovarian cancer: an analysis of the SEER cancer database	14
Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice	14
Nomogram predicting the likelihood of parametrial involvement in early-stage cervical cancer: avoiding unjustified radical hysterectomies	14
Not all high-intermediate risk endometrial cancers are created equal: recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy in all possible subgroups of early	14
Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma	14
Outcomes of splenectomy during primary cytoreductive surgery in ovarian cancer	14
Perioperative outcomes in obese women with uterine cancer	14
Racial disparities in survival for high-grade uterine cancer: a Surveillance, Epidemiology and End Results analysis	14
Real-world data from a Molecular Tumor Board: improved outcomes in gynecologic and breast cancer patients with precision medicine	14
Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775 (177)	14
Menopausal symptoms, sexual dysfunction, and hormone therapy use in young cervical cancer patients undergoing definitive treatment at a single institution	14
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	14
Turning up the heat: Oncolytic virus MEM-288 induces anti-tumoral immune response in pre-clinical models of high grade serous ovarian cancer (190)	14
Presentation of ovarian cancer in women with BRCA mutations	14
Real-world analysis of survival outcomes and toxicities with PARPi use across indications	14
Higher incidence of venous thromboembolism associated with increasing lines of chemotherapy in heavy treated recurrent ovarian cancer patients (054)	13
Impact of implementation of a nutrition support program in ovarian cancer patients	13
Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases (597)	13
Impact of COVID-19 pandemic on United States gynecology resident education	13
Disparities in allocation of research funding for female reproductive cancers based on race-specific disease burden (015)	13
The consequence of obesity on the risk of uterine cancer incidence in younger vs. older adults (053)	13
Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia	13
Impact of surgeon type and rurality on treatment and survival of ovarian cancer patients	13
Life after LACC: a survey of practices and attitudes among gynecologic oncologists in the practice of sentinel lymph node mapping for early-stage cervical cancer	13
Inducing homologous recombination deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor in uterine serous cancer (USC)	13
Combating the financial burden of ovarian cancer: It takes a village (038)	13
Impact of BMI on chemotherapy dosing and survival in endometrial cancer	13
PIK3CA and ARID1A mutations in recurrent/metastatic cervical cancer: The NRG Oncology/Gynecologic Oncology Group-0240 National Institutes of Health Beau Biden Cancer Moonshot (LBA 2)	13
STICn’ around: Spatial resolution of the dysplastic fallopian tube reveals early evidence of immune escape (159)	13
Impact of primary and secondary cytoreduction in BRCA mutated (BRCAm) patients with ovarian/peritoneal/tubal carcinoma	13
Final primary analysis in the original cohort of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer	13
Is there a need for consultant team for bowel resection? An evaluation of surgical outcomes of bowel resection at time of ovarian cytoreductive surgery	13
ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039)	13
Surgical stress promotes IL-6–driven tumor progression in ovarian cancer (047)	13
Prediction of high-grade serous ovarian cancer (HGSC) using DNA methylation patterns with deep machine learning (ML) (032)	13
Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11	13
Cervical cancer recurrence among women undergoing surgery for early-stage disease (027)	13
Colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery? (598)	13
UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of Upitifamab Rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate in platinum-sensitive recurrent ovarian cancer (1248)	12
Avera/Sema4 oncology and analytics protocol (ASAP): Quantification of HER2 protein expression and activation status in gynecologic malignancies utilizing reverse-phase protein array (RPPA) (1267)	12
ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-	12
SYNE1 mutation is associated with increased tumor mutation burden and immune cell infiltration in ovarian cancer (1263)	12
VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resista	12